A Phase 2 interventional study of mRNA-1283 and mRNA-1283.211 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is one of 8 that started in 2021, is one of 5 in phase 2, and was the 11th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 10 · Phase 4 4
First in 2020; this study’s year is marked. 8 started in 2021.
This study's enrollment of 540 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 988 across the 22 interventional studies, 8,691 across the 12 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
4 of the studies in COVID-19 by Moderna, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
| NCT06189053ModernaTX, Inc.A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in COVID-19 by Moderna, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates. The main goal of Part B of this study is to assess the safety, reactogenicity, and immunogenicity of the mRNA-1283.529 booster vaccine candidate.
Part A of this study will assess whether a single dose of mRNA-1283 at three different dose levels or mRNA-1283.211 at two different dose levels will boost antibody responses to the Wuhan-Hu-1 (ancestral strain of SARS-CoV-2) virus, and to the B.1.351 variant, and potentially other SARS-CoV-2 variants, and it will also be used to select a dose for subsequent clinical evaluation. The study will include an active comparator group of participants who will receive mRNA-1273.
Participants in Part A who received the primary series of mRNA-1273 with appropriate documentation at least 6 months prior will be randomized 1:1:1:1:1:1 to receive a single boost of mRNA-1283 at one of three dose levels, a single boost of mRNA-1283.211 at one of two dose levels, or a single dose of the active comparator, mRNA-1273.
Part B of this study will assess whether a single dose of mRNA-1283.529 at two different dose levels as the second booster after a first booster of mRNA- 1273, at least 3 months prior, will boost antibody response to the ancestral strain of the SARS-CoV-2 virus, the B.1.1.529 variant, and potentially other SARS-CoV-2 variants, and inform dose selection for mRNA-1283.529 booster vaccine candidate for subsequent clinical evaluation.
Participants in Part B who received the primary series of mRNA 1273 and who received a first booster dose of mRNA-1273 at least 3 months prior will be enrolled in a 1:1 ratio to receive a single boost of mRNA 1283.529 at one of two dose levels.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 540 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.
Biological: mRNA-1283
Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.
Biological: mRNA-1283
Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.
Biological: mRNA-1283
Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.
Biological: mRNA-1283.211
Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.
Biological: mRNA-1283.211
Participants will receive single IM injection of mRNA-1273 on Day 1.
Biological: mRNA-1273
Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.
Biological: mRNA-1283.529
Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 2 on Day 1.
Biological: mRNA-1283.529
Parts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs)
An AR is any adverse event (AE) related to the IP injection. Solicited local ARs included pain at injection site, erythema (redness) at injection site, swelling (hardness) at injection site, localized axillary swelling or tenderness ipsilateral to the injection arm, and groin or underarm swelling or tenderness ipsilateral to the side of injection. Solicited systemic ARs included headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, fever, chills, irritability/crying, sleepiness, and loss of appetite. Note, not all solicited ARs were considered AEs. The Investigator determined if solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to Day 7
Parts A and B: Number of Participants With Unsolicited AEs
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to Day 28
Parts A and B: Number of Participants With Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study Participation and AEs of Special Interest (AESIs)
SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 to Day 366
Part A: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Neutralizing Antibody (nAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
The GMT (50% inhibitory dose \[ID50\]) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 variant B.1.351 are reported.
Time frame: Day 29
Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
The GMFR measures the changes in immunogenicity titers or levels within participants.
Time frame: Day 29
Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
Seroresponse was defined as an increase of SARS-CoV-2 specific binding antibody (bAb) level or nAb titer to at least 4x lower limit of quantification (LLOQ) if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
Time frame: Day 29
Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.
Time frame: Day 29
Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
The GMFR measures the changes in immunogenicity titers or levels within participants.
Time frame: Day 29
Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)
Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
Time frame: Day 29
Part A: GMT of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
The GMT (ID50) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.
Time frame: Days 1, 29, 91, 181, and 366
Part A: GMT of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
The GMT of bAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.
Time frame: Days 1, 29, 91, 181, and 366
Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.
Time frame: Days 1, 29, 91, 181, and 366
Part B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
The GMT of bAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.
Time frame: Days 1, 29, 91, 181, and 366
Part A: GMFR of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
The GMFR measures the changes in immunogenicity titers or levels within participants.
Time frame: Days 29, 91, 181, and 366
Part A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
The GMFR measures the changes in immunogenicity titers or levels within participants.
Time frame: Days 29, 91, 181, and 366
Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
The GMFR measures the changes in immunogenicity titers or levels within participants.
Time frame: Days 29, 91, 181, and 366
Part B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
The GMFR measures the changes in immunogenicity titers or levels within participants.
Time frame: Days 29, 91, 181, and 366
Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
Time frame: Days 29, 91, 181, and 366
Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)
Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
Time frame: Days 29, 91, 181, and 366
Number of Deaths Related to Study Drug
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
Time frame: Day 1 to Day 366
| Milestone | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|---|---|---|---|---|---|
| Started | 57 | 63 | 56 | 53 | 54 | 57 | 0 | 0 |
| Received at least 1 dose of study drug | 57 | 63 | 56 | 53 | 54 | 57 | 0 | 0 |
| Completed | 51 | 52 | 54 | 49 | 48 | 47 | 0 | 0 |
| Not completed | 6 | 11 | 2 | 4 | 6 | 10 | 0 | 0 |
| Withdrew: Other than specified | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 1 | 1 | 3 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 7 | 1 | 3 | 3 | 8 | 0 | 0 |
| Milestone | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 103 | 97 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 103 | 97 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 98 | 88 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 9 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
An AR is any adverse event (AE) related to the IP injection. Solicited local ARs included pain at injection site, erythema (redness) at injection site, swelling (hardness) at injection site, localized axillary swelling or tenderness ipsilateral to the injection arm, and groin or underarm swelling or tenderness ipsilateral to the side of injection. Solicited systemic ARs included headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, fever, chills, irritability/crying, sleepiness, and loss of appetite. Note, not all solicited ARs were considered AEs. The Investigator determined if solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|---|---|---|---|---|---|
| Solicited Local ARs | 30 | 40 | 37 | 28 | 29 | 46 | 46 | 69 |
| Solicited Systemic ARs | 32 | 39 | 35 | 39 | 27 | 41 | 51 | 60 |
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|---|---|---|---|---|---|
| Parts A and B: Number of Participants With Unsolicited AEs | 13 | 9 | 11 | 12 | 7 | 8 | 13 | 11 |
SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|---|---|---|---|---|---|
| SAEs | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 6 |
| MAAEs | 25 | 23 | 27 | 24 | 18 | 23 | 51 | 42 |
| AEs Leading to Withdrawal from Study Participation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| AESIs | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
The GMT (50% inhibitory dose \[ID50\]) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 variant B.1.351 are reported.
| Titer | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Ancestral SARS-CoV-2 ID50 | 4751.7 (3207.0 to 7040.5) | 5666.5 (4149.3 to 7738.4) | 7723.0 (5621.7 to 10609.7) | 5105.5 (3083.3 to 8453.9) | 4729.8 (2572.4 to 8696.3) | 3562.9 (2550.1 to 4977.9) |
| SARS-CoV-2 Variant B.1.351 ID50 | 946.7 (611.4 to 1465.7) | 1216.2 (838.9 to 1763.3) | 2020.1 (1350.7 to 3021.1) | 1566.3 (942.4 to 2603.2) | 1224.8 (660.6 to 2271.0) | 964.4 (659.6 to 1410.1) |
The GMFR measures the changes in immunogenicity titers or levels within participants.
| Ratio | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Ancestral SARS-CoV-2 ID50 | 26.8 (16.8 to 42.8) | 34.3 (20.9 to 56.0) | 45.3 (27.0 to 76.0) | 35.5 (18.1 to 69.6) | 28.1 (13.2 to 59.9) | 24.5 (14.7 to 40.7) |
| SARS-CoV-2 Variant B.1.351 ID50 | 27.4 (16.2 to 46.6) | 33.7 (21.1 to 53.9) | 52.1 (30.2 to 89.8) | 54.2 (27.2 to 107.7) | 41.8 (20.8 to 84.0) | 35.8 (19.8 to 64.6) |
Seroresponse was defined as an increase of SARS-CoV-2 specific binding antibody (bAb) level or nAb titer to at least 4x lower limit of quantification (LLOQ) if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
| Participants | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Ancestral SARS-CoV-2 ID50 | 28 | 35 | 30 | 22 | 19 | 26 |
| SARS-CoV-2 Variant B.1.351 ID50 | 26 | 35 | 31 | 22 | 19 | 25 |
The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.
| Titer | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) | 1562.9 (1113.4 to 2194.0) | 2723.0 (1938.3 to 3825.4) |
The GMFR measures the changes in immunogenicity titers or levels within participants.
| Ratio | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) | 7.2 (5.7 to 9.0) | 7.8 (5.9 to 10.4) |
Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
| Participants | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529) | 55 | 48 |
The GMT (ID50) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.
| Titer | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Day 1 Ancestral SARS-CoV-2 ID50 | 177.4 (108.5 to 290.0) | 165.4 (114.4 to 239.2) | 170.4 (104.4 to 278.0) | 143.7 (97.0 to 213.1) | 168.6 (74.5 to 381.3) | 145.6 (91.9 to 230.7) |
| Day 29 Ancestral SARS-CoV-2 ID50 | 4751.7 (3207.0 to 7040.5) | 5666.5 (4149.3 to 7738.4) | 7723.0 (5621.7 to 10609.7) | 5105.5 (3083.3 to 8453.9) | 4729.8 (2572.4 to 8696.3) | 3562.9 (2550.1 to 4977.9) |
| Day 91 Ancestral SARS-CoV-2 ID50 | 3980.4 (2459.2 to 6442.6) | 4589.2 (3285.9 to 6409.4) | 6754.5 (4604.3 to 9909.0) | 4943.1 (3029.0 to 8066.9) | 4319.8 (2758.9 to 6763.7) | 3155.1 (1980.2 to 5027.0) |
| Day 181 Ancestral SARS-CoV-2 ID50 | 2476.4 (1400.5 to 4378.8) | 2861.4 (1879.2 to 4357.1) | 3834.7 (2606.2 to 5642.2) | 2960.3 (1805.5 to 4853.6) | 2767.2 (1588.2 to 4821.6) | 1269.4 (809.8 to 1990.0) |
| Day 366 Ancestral SARS-CoV-2 ID50 | 1497.4 (723.2 to 3100.5) | 3097.6 (2003.1 to 4790.2) | 2921.1 (2062.2 to 4137.8) | 2013.3 (1225.1 to 3308.5) | 1539.6 (772.8 to 3067.3) | 1336.1 (739.4 to 2414.2) |
| Day 1 SARS-CoV-2 Variant B.1.351 ID50 | 34.5 (21.0 to 56.5) | 36.1 (25.9 to 50.3) | 38.8 (24.0 to 62.6) | 28.9 (19.0 to 44.0) | 29.3 (14.2 to 60.4) | 27.9 (17.5 to 44.6) |
| Day 29 SARS-CoV-2 Variant B.1.351 ID50 | 946.7 (611.4 to 1465.7) | 1216.2 (838.9 to 1763.3) | 2020.1 (1350.7 to 3021.1) | 1566.3 (942.4 to 2603.2) | 1224.8 (660.6 to 2271.0) | 964.4 (659.6 to 1410.1) |
| Day 91 SARS-CoV-2 Variant B.1.351 ID50 | 794.8 (461.9 to 1367.5) | 965.6 (631.0 to 1477.7) | 1520.8 (1025.7 to 2254.8) | 1105.8 (579.9 to 2108.6) | 990.5 (591.0 to 1660.0) | 640.2 (384.2 to 1066.7) |
| Day 181 SARS-CoV-2 Variant B.1.351 ID50 | 786.3 (403.1 to 1533.7) | 760.2 (438.7 to 1317.2) | 1458.4 (916.6 to 2320.5) | 967.2 (531.3 to 1760.7) | 769.6 (429.6 to 1378.9) | 460.5 (266.1 to 796.9) |
| Day 366 SARS-CoV-2 Variant B.1.351 ID50 | 581.2 (279.7 to 1207.6) | 1461.8 (855.0 to 2499.1) | 1259.6 (789.7 to 2009.1) | 790.3 (397.0 to 1573.3) | 530.3 (223.4 to 1258.4) | 534.2 (252.1 to 1132.1) |
The GMT of bAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.
| Titer | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Day 1 Ancestral SARS-CoV-2 | 29458.4 (18988.8 to 45700.5) | 29839.6 (21775.9 to 40889.2) | 32632.4 (22347.8 to 47650.0) | 28886.5 (21389.0 to 39012.1) | 30803.7 (17375.8 to 54608.8) | 30644.3 (21431.7 to 43817.0) |
| Day 29 Ancestral SARS-CoV-2 | 717040.9 (545647.9 to 942269.9) | 737925.6 (580477.3 to 938080.1) | 1070144.5 (823120.1 to 1391302.9) | 835783.7 (570117.5 to 1225246.2) | 688909.2 (429957.5 to 1103820.5) | 594926.9 (462362.9 to 765498.3) |
| Day 91 Ancestral SARS-CoV-2 | 538518.6 (370446.8 to 782844.8) | 575062.5 (432778.8 to 764124.4) | 785822.0 (601645.3 to 1026379.3) | 613915.9 (398665.6 to 945385.7) | 629867.6 (446549.5 to 888441.8) | 390985.5 (289339.3 to 528340.5) |
| Day 181 Ancestral SARS-CoV-2 | 349027.0 (227163.4 to 536265.3) | 338163.9 (239965.4 to 476547.2) | 447634.3 (336503.1 to 595467.0) | 370694.6 (257195.7 to 534280.0) | 358399.9 (238972.0 to 537512.6) | 198042.8 (141579.1 to 277025.1) |
| Day 366 Ancestral SARS-CoV-2 | 220315.4 (125437.1 to 386957.9) | 390137.4 (266323.9 to 571511.7) | 370475.8 (277402.5 to 494776.9) | 260942.1 (185711.7 to 366647.8) | 246749.8 (150746.4 to 403893.4) | 163960.1 (107650.0 to 249725.1) |
| Day 1 SARS-CoV-2 Variant B.1.351 | 12499.8 (8275.5 to 18880.3) | 13289.6 (9765.0 to 18086.4) | 15875.3 (10891.6 to 23139.3) | 15255.0 (10255.8 to 22691.2) | 12664.6 (7792.9 to 20581.8) | 17401.8 (11236.5 to 26950.0) |
| Day 29 SARS-CoV-2 Variant B.1.351 | 359208.1 (259502.7 to 497221.9) | 369055.6 (277237.5 to 491282.7) | 504673.7 (387088.6 to 657977.5) | 399270.2 (261474.1 to 609684.5) | 352867.0 (193718.3 to 642763.9) | 333866.2 (264529.3 to 421377.3) |
| Day 91 SARS-CoV-2 Variant B.1.351 | 237940.9 (154308.2 to 366901.3) | 271701.9 (194943.5 to 378683.7) | 362689.3 (275141.6 to 478093.9) | 245501.5 (154897.5 to 389102.6) | 330103.6 (246861.3 to 441415.5) | 202152.0 (158047.0 to 258564.9) |
| Day 181 SARS-CoV-2 Variant B.1.351 | 151202.9 (90854.0 to 251638.2) | 143620.7 (94068.8 to 219274.8) | 184376.3 (134452.0 to 252838.3) | 142996.2 (92494.0 to 221072.9) | 183952.8 (130226.4 to 259844.8) | 95496.2 (70938.4 to 128555.5) |
| Day 366 SARS-CoV-2 Variant B.1.351 | 105204.5 (53545.8 to 206701.3) | 218574.3 (128094.7 to 372964.0) | 203600.7 (133854.9 to 309687.7) | 121911.8 (68950.3 to 215553.6) | 134120.4 (70688.7 to 254471.9) | 89012.3 (53840.6 to 147160.1) |
The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.
| Titer | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Day 1 SARS-CoV-2 Variant B.1.1.529 ID50 | 217.6 (162.0 to 292.4) | 349.2 (239.7 to 508.7) |
| Day 29 SARS-CoV-2 Variant B.1.1.529 ID50 | 1562.9 (1113.4 to 2194.0) | 2723.0 (1938.3 to 3825.4) |
| Day 91 SARS-CoV-2 Variant B.1.1.529 ID50 | 978.5 (667.7 to 1434.0) | 1713.5 (1238.2 to 2371.4) |
| Day 181 SARS-CoV-2 Variant B.1.1.529 ID50 | 724.0 (500.9 to 1046.5) | 1608.7 (1053.9 to 2455.5) |
| Day 366 SARS-CoV-2 Variant B.1.1.529 ID50 | 666.0 (395.5 to 1121.8) | 1873.7 (1156.9 to 3034.9) |
The GMT of bAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.
| Titer | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Day 1 SARS-CoV-2 Variant B.1.1.529 | 50830.3 (41890.8 to 61677.5) | 61419.3 (49407.6 to 76351.2) |
| Day 29 SARS-CoV-2 Variant B.1.1.529 | 182046.9 (153016.2 to 216585.4) | 233677.5 (189382.6 to 288332.8) |
| Day 91 SARS-CoV-2 Variant B.1.1.529 | 118658.1 (97721.5 to 144080.3) | 157262.3 (126717.0 to 195170.7) |
| Day 181 SARS-CoV-2 Variant B.1.1.529 | 73469.5 (58947.0 to 91569.8) | 103322.9 (81221.9 to 131437.7) |
| Day 366 SARS-CoV-2 Variant B.1.1.529 | 46721.5 (32757.5 to 66638.1) | 98989.7 (67965.4 to 144175.8) |
The GMFR measures the changes in immunogenicity titers or levels within participants.
| Ratio | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Day 29 Ancestral SARS-CoV-2 ID50 | 26.8 (16.8 to 42.8) | 34.3 (20.9 to 56.0) | 45.3 (27.0 to 76.0) | 35.5 (18.1 to 69.6) | 28.1 (13.2 to 59.9) | 24.5 (14.7 to 40.7) |
| Day 91 Ancestral SARS-CoV-2 ID50 | 22.4 (13.5 to 37.4) | 27.1 (16.5 to 44.6) | 39.6 (23.0 to 68.3) | 34.0 (17.2 to 67.1) | 25.6 (12.2 to 53.9) | 21.7 (12.4 to 38.0) |
| Day 181 Ancestral SARS-CoV-2 ID50 | 13.9 (7.4 to 26.0) | 17.1 (9.9 to 29.7) | 23.6 (13.2 to 42.1) | 20.6 (11.1 to 38.2) | 15.3 (7.6 to 30.7) | 8.2 (4.6 to 14.6) |
| Day 366 Ancestral SARS-CoV-2 ID50 | 9.1 (4.3 to 19.2) | 18.0 (9.5 to 33.9) | 17.8 (10.3 to 30.6) | 13.7 (7.1 to 26.4) | 9.8 (4.1 to 23.3) | 8.7 (4.3 to 17.6) |
| Day 29 SARS-CoV-2 Variant B.1.351 ID50 | 27.4 (16.2 to 46.6) | 33.7 (21.1 to 53.9) | 52.1 (30.2 to 89.8) | 54.2 (27.2 to 107.7) | 41.8 (20.8 to 84.0) | 35.8 (19.8 to 64.6) |
| Day 91 SARS-CoV-2 Variant B.1.351 ID50 | 23.0 (12.8 to 41.6) | 27.0 (16.5 to 44.4) | 39.2 (21.9 to 70.3) | 38.1 (16.9 to 85.9) | 33.8 (17.7 to 64.6) | 23.9 (12.7 to 45.3) |
| Day 181 SARS-CoV-2 Variant B.1.351 ID50 | 21.4 (10.1 to 45.1) | 21.4 (12.3 to 37.2) | 39.3 (21.0 to 73.4) | 33.4 (15.8 to 70.6) | 24.9 (12.6 to 49.4) | 16.5 (8.3 to 32.8) |
| Day 366 SARS-CoV-2 Variant B.1.351 ID50 | 17.6 (8.0 to 38.7) | 38.2 (20.0 to 73.2) | 32.5 (17.6 to 59.7) | 27.4 (12.3 to 61.0) | 20.0 (7.9 to 50.4) | 18.9 (8.0 to 44.7) |
The GMFR measures the changes in immunogenicity titers or levels within participants.
| Ratio | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Day 29 Ancestral SARS-CoV-2 | 24.3 (16.1 to 36.9) | 24.7 (16.2 to 37.7) | 32.8 (21.4 to 50.2) | 28.9 (16.2 to 51.6) | 22.4 (12.1 to 41.4) | 19.8 (12.4 to 31.4) |
| Day 91 Ancestral SARS-CoV-2 | 17.5 (11.3 to 27.2) | 19.0 (12.1 to 29.8) | 24.1 (15.6 to 37.3) | 20.9 (11.3 to 38.5) | 20.4 (12.2 to 34.3) | 12.8 (8.2 to 20.0) |
| Day 181 Ancestral SARS-CoV-2 | 11.5 (7.1 to 18.7) | 11.2 (6.9 to 18.2) | 14.0 (8.8 to 22.3) | 12.8 (7.6 to 21.8) | 11.6 (6.8 to 20.0) | 6.2 (3.9 to 9.9) |
| Day 366 Ancestral SARS-CoV-2 | 8.5 (4.8 to 15.0) | 12.9 (7.5 to 22.1) | 11.4 (7.4 to 17.5) | 8.8 (5.3 to 14.8) | 8.5 (4.5 to 16.1) | 5.3 (3.0 to 9.4) |
| Day 29 SARS-CoV-2 Variant B.1.351 | 28.7 (18.9 to 43.8) | 27.8 (17.6 to 43.8) | 31.8 (20.3 to 49.8) | 26.2 (14.1 to 48.7) | 27.9 (13.1 to 59.4) | 19.8 (12.0 to 32.7) |
| Day 91 SARS-CoV-2 Variant B.1.351 | 18.1 (11.4 to 28.7) | 20.5 (12.7 to 33.1) | 22.8 (14.0 to 37.4) | 15.9 (8.1 to 31.0) | 26.1 (15.1 to 45.0) | 11.7 (7.5 to 18.3) |
| Day 181 SARS-CoV-2 Variant B.1.351 | 11.5 (6.8 to 19.6) | 10.8 (6.3 to 18.4) | 11.9 (7.1 to 20.0) | 9.4 (5.2 to 17.0) | 15.0 (8.5 to 26.6) | 5.1 (3.2 to 8.2) |
| Day 366 SARS-CoV-2 Variant B.1.351 | 8.3 (4.4 to 16.0) | 17.1 (9.4 to 31.1) | 12.9 (7.6 to 21.7) | 7.7 (3.4 to 17.5) | 12.4 (6.0 to 25.5) | 5.2 (2.7 to 9.8) |
The GMFR measures the changes in immunogenicity titers or levels within participants.
| Ratio | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Day 29 SARS-CoV-2 Variant B.1.1.529 ID50 | 7.2 (5.7 to 9.0) | 7.8 (5.9 to 10.4) |
| Day 91 SARS-CoV-2 Variant B.1.1.529 ID50 | 4.6 (3.3 to 6.3) | 5.0 (3.6 to 6.8) |
| Day 181 SARS-CoV-2 Variant B.1.1.529 ID50 | 3.4 (2.3 to 5.0) | 4.5 (2.8 to 7.3) |
| Day 366 SARS-CoV-2 Variant B.1.1.529 ID50 | 2.5 (1.5 to 4.3) | 6.4 (3.3 to 12.6) |
The GMFR measures the changes in immunogenicity titers or levels within participants.
| Ratio | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Day 29 | 3.6 (3.0 to 4.3) | 3.8 (3.2 to 4.5) |
| Day 91 | 2.3 (1.9 to 2.8) | 2.5 (2.0 to 3.0) |
| Day 181 | 1.5 (1.2 to 1.8) | 1.6 (1.3 to 2.0) |
| Day 366 | 0.9 (0.6 to 1.2) | 1.7 (1.1 to 2.6) |
Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
| Participants | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 |
|---|---|---|---|---|---|---|
| Day 29 Ancestral SARS-CoV-2 ID50 | 28 | 35 | 30 | 22 | 19 | 26 |
| Day 91 Ancestral SARS-CoV-2 ID50 | 27 | 32 | 29 | 20 | 19 | 26 |
| Day 181 Ancestral SARS-CoV-2 ID50 | 24 | 29 | 27 | 19 | 17 | 17 |
| Day 366 Ancestral SARS-CoV-2 ID50 | 18 | 25 | 27 | 18 | 12 | 14 |
| Day 29 SARS-CoV-2 Variant B.1.351 ID50 | 26 | 35 | 31 | 22 | 19 | 25 |
| Day 91 SARS-CoV-2 Variant B.1.351 ID50 | 26 | 33 | 29 | 20 | 20 | 24 |
| Day 181 SARS-CoV-2 Variant B.1.351 ID50 | 23 | 30 | 28 | 22 | 17 | 20 |
| Day 366 SARS-CoV-2 Variant B.1.351 ID50 | 17 | 27 | 28 | 17 | 14 | 16 |
Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.
| Participants | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|
| Day 29 ID50 | 55 | 48 |
| Day 91 ID50 | 32 | 35 |
| Day 181 ID50 | 26 | 28 |
| Day 366 ID50 | 20 | 24 |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
| Participants | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose |
|---|---|---|---|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Deaths related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Day 1 to Day 366. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: mRNA-1283 2.5ug Booster | 0/57 (0%) | 2/57 (3.5%) | 15/57 (26.3%) |
| Part A: mRNA-1283 5ug Booster | 0/64 (0%) | 1/64 (1.6%) | 13/64 (20.3%) |
| Part A: mRNA-1283 10ug Booster | 0/56 (0%) | 2/56 (3.6%) | 16/56 (28.6%) |
| Part A: mRNA-1283.211 5ug Booster | 0/52 (0%) | 3/52 (5.8%) | 18/52 (34.6%) |
| Part A: mRNA-1283.211 10ug Booster | 0/54 (0%) | 3/54 (5.6%) | 12/54 (22.2%) |
| Part A: mRNA-1273 50ug Booster | 0/57 (0%) | 2/57 (3.5%) | 16/57 (28.1%) |
| Part B: mRNA-1283.529 5ug Booster | 0/103 (0%) | 2/103 (1.9%) | 24/103 (23.3%) |
| Part B: mRNA-1283.529 10ug Booster | 2/97 (2.1%) | 6/97 (6.2%) | 24/97 (24.7%) |
| Event | Part A: mRNA-1283 2.5ug Booster | Part A: mRNA-1283 5ug Booster | Part A: mRNA-1283 10ug Booster | Part A: mRNA-1283.211 5ug Booster | Part A: mRNA-1283.211 10ug Booster | Part A: mRNA-1273 50ug Booster | Part B: mRNA-1283.529 5ug Booster | Part B: mRNA-1283.529 10ug Booster |
|---|---|---|---|---|---|---|---|---|
| Herpes zosterInfections and infestations | 0/57 | 0/64 | 0/56 | 1/52 | 1/54 | 0/57 | 0/103 | 0/97 |
| Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 0/64 | 0/56 | 1/52 | 0/54 | 0/57 | 0/103 | 0/97 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/57 | 0/64 | 0/56 | 1/52 | 0/54 | 0/57 | 0/103 | 0/97 |
| Cerebrospinal fluid leakageNervous system disorders | 0/57 | 0/64 | 0/56 | 1/52 | 0/54 | 0/57 | 0/103 | 0/97 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/57 | 0/64 | 0/56 | 1/52 | 0/54 | 0/57 | 0/103 | 0/97 |
| Staphylococcal infectionInfections and infestations | 0/57 | 0/64 | 0/56 | 0/52 | 1/54 | 0/57 | 0/103 | 0/97 |
| Small intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 0/64 | 0/56 | 0/52 | 1/54 | 0/57 | 0/103 | 0/97 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 0/64 | 1/56 | 0/52 | 0/54 | 0/57 | 0/103 | 0/97 |
| Small intestinal obstructionGastrointestinal disorders | 0/57 | 0/64 | 1/56 | 0/52 | 0/54 | 0/57 | 0/103 | 0/97 |
| AppendicitisInfections and infestations | 1/57 | 0/64 | 0/56 | 0/52 | 0/54 | 0/57 | 0/103 | 1/97 |
| Event | Part A: mRNA-1283 2.5ug Booster | Part A: mRNA-1283 5ug Booster | Part A: mRNA-1283 10ug Booster | Part A: mRNA-1283.211 5ug Booster | Part A: mRNA-1283.211 10ug Booster | Part A: mRNA-1273 50ug Booster | Part B: mRNA-1283.529 5ug Booster | Part B: mRNA-1283.529 10ug Booster |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/57 | 8/64 | 8/56 | 5/52 | 6/54 | 6/57 | 14/103 | 17/97 |
| HypertensionVascular disorders | 4/57 | 1/64 | 2/56 | 1/52 | 0/54 | 0/57 | 5/103 | 4/97 |
| NasopharyngitisInfections and infestations | 1/57 | 1/64 | 2/56 | 3/52 | 2/54 | 1/57 | 0/103 | 3/97 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/57 | 0/64 | 1/56 | 3/52 | 1/54 | 1/57 | 2/103 | 2/97 |
| Back painMusculoskeletal and connective tissue disorders | 0/57 | 0/64 | 0/56 | 3/52 | 1/54 | 2/57 | 2/103 | 2/97 |
| Influenza like illnessGeneral disorders | 0/57 | 1/64 | 1/56 | 3/52 | 1/54 | 0/57 | 0/103 | 0/97 |
| InfluenzaInfections and infestations | 3/57 | 1/64 | 1/56 | 1/52 | 1/54 | 1/57 | 0/103 | 4/97 |
| Respiratory tract infection viralInfections and infestations | 1/57 | 0/64 | 1/56 | 1/52 | 0/54 | 3/57 | 1/103 | 2/97 |
| AnxietyPsychiatric disorders | 0/57 | 2/64 | 1/56 | 1/52 | 0/54 | 3/57 | 3/103 | 2/97 |
| Irritable bowel syndromeGastrointestinal disorders | 0/57 | 0/64 | 0/56 | 0/52 | 0/54 | 3/57 | 0/103 | 0/97 |
Measured in the Safety Set, which consisted of all randomized/enrolled (Part A: randomized, Part B: enrolled) participants who received one dose of investigational product (IP). Data in the Safety Set is presented per actual dose received. There was 1 participant in the mRNA-1283.211 low dose group who had a dosing error and received mRNA-1283 at medium dose.
| Age, Customized(Participants) | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| >=18 and <56 Years | 40 | 46 | 42 | 37 | 40 | 42 | 44 | 59 | 350 |
| >=56 Years | 17 | 18 | 14 | 15 | 14 | 15 | 59 | 38 | 190 |
| Sex: Female, Male(Participants) | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 31 | 43 | 32 | 34 | 39 | 32 | 70 | 62 | 343 |
| Male | 26 | 21 | 24 | 18 | 15 | 25 | 33 | 35 | 197 |
| Ethnicity (NIH/OMB)(Participants) | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 14 | 8 | 9 | 8 | 11 | 2 | 4 | 66 |
| Not Hispanic or Latino | 47 | 50 | 47 | 43 | 43 | 45 | 100 | 93 | 468 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 3 | 1 | 1 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Part A: mRNA-1283 Low Dose | Part A: mRNA-1283 Medium Dose | Part A: mRNA-1283 High Dose | Part A: mRNA-1283.211 Low Dose | Part A: mRNA-1283.211 High Dose | Part A: mRNA-1273 | Part B: mRNA-1283.529 Low Dose | Part B: mRNA-1283.529 High Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 3 |
| Asian | 5 | 1 | 3 | 3 | 3 | 3 | 0 | 2 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 11 | 11 | 9 | 9 | 10 | 6 | 7 | 7 | 70 |
| White | 41 | 48 | 41 | 38 | 37 | 47 | 94 | 88 | 434 |
| More than one race | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 6 |
| Unknown or Not Reported | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2021 to primary completion in Mar 2023, 15 months.
Results were first posted in Jul 2025, 2 years 3 months after primary completion. A results delay was requested in Mar 2024.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 15 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MRNA-1283